Analysts Set Envista Holdings Co. (NYSE:NVST) PT at $29.60

Envista Holdings Co. (NYSE:NVST) has received a consensus recommendation of “Reduce” from the eleven research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $27.90.

Several analysts have recently commented on NVST shares. TheStreet cut Envista from a “c” rating to a “d+” rating in a research report on Wednesday, February 7th. SVB Leerink assumed coverage on Envista in a research report on Monday, February 26th. They set an “underperform” rating and a $19.00 price objective for the company. UBS Group assumed coverage on Envista in a research report on Friday, January 5th. They set a “neutral” rating and a $26.00 price objective for the company. Leerink Partnrs reissued an “underperform” rating on shares of Envista in a research report on Monday, February 26th. Finally, Morgan Stanley cut Envista from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $33.00 to $21.00 in a research report on Friday.

Institutional Trading of Envista

A number of institutional investors and hedge funds have recently made changes to their positions in NVST. DnB Asset Management AS increased its stake in shares of Envista by 33.4% in the third quarter. DnB Asset Management AS now owns 56,749 shares of the company’s stock worth $1,582,000 after purchasing an additional 14,216 shares during the period. Oak Thistle LLC bought a new position in shares of Envista in the third quarter worth about $1,568,000. Corbyn Investment Management Inc. MD increased its stake in shares of Envista by 93.2% in the third quarter. Corbyn Investment Management Inc. MD now owns 73,437 shares of the company’s stock worth $2,047,000 after purchasing an additional 35,420 shares during the period. Handelsbanken Fonder AB increased its stake in Envista by 9.5% during the third quarter. Handelsbanken Fonder AB now owns 925,600 shares of the company’s stock valued at $25,806,000 after acquiring an additional 80,000 shares during the period. Finally, HGK Asset Management Inc. increased its stake in Envista by 13.1% during the third quarter. HGK Asset Management Inc. now owns 18,376 shares of the company’s stock valued at $512,000 after acquiring an additional 2,129 shares during the period.

Envista Stock Performance

Shares of Envista stock opened at $20.39 on Wednesday. The stock has a market cap of $3.50 billion, a PE ratio of -33.43, a price-to-earnings-growth ratio of 3.79 and a beta of 1.35. The business has a fifty day simple moving average of $20.95 and a 200-day simple moving average of $22.72. The company has a quick ratio of 1.90, a current ratio of 2.23 and a debt-to-equity ratio of 0.33. Envista has a 12 month low of $18.95 and a 12 month high of $38.68.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 7th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.04). The business had revenue of $645.60 million during the quarter, compared to analyst estimates of $638.37 million. Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. During the same period last year, the business earned $0.52 EPS. On average, sell-side analysts anticipate that Envista will post 1.43 EPS for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.